FELIQS Appoints Gregory Kunst and Joe Zenkus to Board of Directors

FUKUOKA, Japan & NEW YORK--(BUSINESS WIRE)--FELIQS Corporation (“FELIQS”), a biotechnology company developing first-in-class small molecule therapeutics targeting oxidized lipids for rare pediatric retinal diseases, today announced the today announced the appointment of two distinguished industry leaders, Gregory Kunst and Joe Zenkus, to its Board of Directors. The appointments follow a recently secured investment aimed at accelerating FELIQS’s clinical programs. Gregory Kunst brings over 20 ye